These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

413 related articles for article (PubMed ID: 32678196)

  • 21. MicroRNA-153-3p regulates cell proliferation and cisplatin resistance via Nrf-2 in esophageal squamous cell carcinoma.
    Zuo J; Zhao M; Fan Z; Liu B; Wang Y; Li Y; Lv P; Xing L; Zhang X; Shen H
    Thorac Cancer; 2020 Mar; 11(3):738-747. PubMed ID: 32012470
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Remarkable inhibition effects of afatinib alone or combining with paclitaxel in esophageal squamous cell carcinoma.
    Yang LY; Cheng ZJ; Liu Z; Wang D; Zhang N; Fan ZL; Cai HQ; Zhang Y; Cai Y; Xu X; Wang JH; Du GH; Hao JJ; Wang MR
    J Gastroenterol Hepatol; 2021 Sep; 36(9):2513-2522. PubMed ID: 33721913
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pristimerin exhibits anti-cancer activity by inducing ER stress and AKT/GSK3β pathway through increasing intracellular ROS production in human esophageal cancer cells.
    Hu WB; Liu YT; Li J; Wang Y; Sun XZ; Hua MY; Liu XT; Hui BN
    Toxicol In Vitro; 2024 Aug; 99():105867. PubMed ID: 38848824
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The histone deacetylase inhibitor panobinostat exerts anticancer effects on esophageal squamous cell carcinoma cells by inducing cell cycle arrest.
    Cheng YW; Liao LD; Yang Q; Chen Y; Nie PJ; Zhang XJ; Xie JJ; Shan BE; Zhao LM; Xu LY; Li EM
    Cell Biochem Funct; 2018 Dec; 36(8):398-407. PubMed ID: 30484863
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Circular RNA circNTRK2 facilitates the progression of esophageal squamous cell carcinoma through up-regulating NRIP1 expression via miR-140-3p.
    Chen X; Jiang J; Zhao Y; Wang X; Zhang C; Zhuan L; Zhang D; Zheng Y
    J Exp Clin Cancer Res; 2020 Jul; 39(1):133. PubMed ID: 32653032
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The PSMD14 inhibitor Thiolutin as a novel therapeutic approach for esophageal squamous cell carcinoma through facilitating SNAIL degradation.
    Jing C; Li X; Zhou M; Zhang S; Lai Q; Liu D; Ye B; Li L; Wu Y; Li H; Yue K; Chen P; Yao X; Wu Y; Duan Y; Wang X
    Theranostics; 2021; 11(12):5847-5862. PubMed ID: 33897885
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Integrated transcriptomics explored the cancer-promoting genes CDKN3 in esophageal squamous cell cancer.
    Wang W; Liao K; Guo HC; Zhou S; Yu R; Liu Y; Pan Y; Pu J
    J Cardiothorac Surg; 2021 May; 16(1):148. PubMed ID: 34044866
    [TBL] [Abstract][Full Text] [Related]  

  • 28. AR-42: A Pan-HDAC Inhibitor with Antitumor and Antiangiogenic Activities in Esophageal Squamous Cell Carcinoma.
    Zhu Y; Yuan T; Zhang Y; Shi J; Bai L; Duan X; Tong R; Zhong L
    Drug Des Devel Ther; 2019; 13():4321-4330. PubMed ID: 31908417
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Long noncoding RNA PANDA promotes esophageal squamous carcinoma cell progress by dissociating from NF-YA but interact with SAFA.
    Shi W; Wang Q; Bian Y; Fan Y; Zhou Y; Feng T; Li Z; Cao X
    Pathol Res Pract; 2019 Oct; 215(10):152604. PubMed ID: 31495606
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Co-targeting PLK1 and mTOR induces synergistic inhibitory effects against esophageal squamous cell carcinoma.
    Liu TT; Yang KX; Yu J; Cao YY; Ren JS; Hao JJ; Pan BQ; Ma S; Yang LY; Cai Y; Wang MR; Zhang Y
    J Mol Med (Berl); 2018 Aug; 96(8):807-817. PubMed ID: 29959473
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Metabolic remodeling by TIGAR overexpression is a therapeutic target in esophageal squamous-cell carcinoma.
    Chu J; Niu X; Chang J; Shao M; Peng L; Xi Y; Lin A; Wang C; Cui Q; Luo Y; Fan W; Chen Y; Sun Y; Guo W; Tan W; Lin D; Wu C
    Theranostics; 2020; 10(8):3488-3502. PubMed ID: 32206103
    [No Abstract]   [Full Text] [Related]  

  • 32. Exosome-mediated transfer of lncRNA PART1 induces gefitinib resistance in esophageal squamous cell carcinoma via functioning as a competing endogenous RNA.
    Kang M; Ren M; Li Y; Fu Y; Deng M; Li C
    J Exp Clin Cancer Res; 2018 Jul; 37(1):171. PubMed ID: 30049286
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Purpurogallin is a novel mitogen-activated protein kinase kinase 1/2 inhibitor that suppresses esophageal squamous cell carcinoma growth in vitro and in vivo.
    Xie X; Zu X; Liu F; Wang T; Wang X; Chen H; Liu K; Wang P; Liu F; Zheng Y; Bode AM; Dong Z; Kim DJ
    Mol Carcinog; 2019 Jul; 58(7):1248-1259. PubMed ID: 31100197
    [TBL] [Abstract][Full Text] [Related]  

  • 34. TIM-3 promotes the metastasis of esophageal squamous cell carcinoma by targeting epithelial-mesenchymal transition via the Akt/GSK-3β/Snail signaling pathway.
    Shan B; Man H; Liu J; Wang L; Zhu T; Ma M; Xv Z; Chen X; Yang X; Li P
    Oncol Rep; 2016 Sep; 36(3):1551-61. PubMed ID: 27430162
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Anticancer effects of suberoylanilide hydroxamic acid in esophageal squamous cancer cells in vitro and in vivo.
    Tzao C; Jin JS; Chen BH; Chung HY; Chang CC; Hsu TY; Sun GH
    Dis Esophagus; 2014; 27(7):693-702. PubMed ID: 24033428
    [TBL] [Abstract][Full Text] [Related]  

  • 36. MTA1 promotes tumorigenesis and development of esophageal squamous cell carcinoma via activating the MEK/ERK/p90RSK signaling pathway.
    Nan P; Wang T; Li C; Li H; Wang J; Zhang J; Dou N; Zhan Q; Ma F; Wang H; Qian H
    Carcinogenesis; 2020 Sep; 41(9):1263-1272. PubMed ID: 31783401
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effects and mechanisms of FBXO31 on Taxol chemoresistance in esophageal squamous cell carcinoma.
    Lv L; Wang SC; Mo JY; Huang KL; Xu ML; Liu J
    Biochem Biophys Res Commun; 2022 Jan; 586():129-136. PubMed ID: 34839191
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Plumbagin, a natural naphthoquinone, inhibits the growth of esophageal squamous cell carcinoma cells through inactivation of STAT3.
    Cao Y; Yin X; Jia Y; Liu B; Wu S; Shang M
    Int J Mol Med; 2018 Sep; 42(3):1569-1576. PubMed ID: 29901084
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Targeting HOX/PBX dimer formation as a potential therapeutic option in esophageal squamous cell carcinoma.
    Shen LY; Zhou T; Du YB; Shi Q; Chen KN
    Cancer Sci; 2019 May; 110(5):1735-1745. PubMed ID: 30844117
    [TBL] [Abstract][Full Text] [Related]  

  • 40. SAMD9 Promotes Postoperative Recurrence of Esophageal Squamous Cell Carcinoma by Stimulating MYH9-Mediated GSK3β/β-Catenin Signaling.
    Li Q; Luo H; Dai FQ; Wang RT; Fan XQ; Luo YY; Deng MS; Wang Y; Long T; Guo W; Xu B; Xu CX; Jin H
    Adv Sci (Weinh); 2023 Apr; 10(11):e2203573. PubMed ID: 36757050
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.